EMBIOSYS INC.
CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer
CuRrEnT: Capecitabine in RCB2/3 with a wearable induced Electric field device in Triple Negative Breast Cancer is a funding opportunity from EMBIOSYS INC., up to 1379442, closing August 31, 2027.
Aug 31, 2027
(396d left)Overview
PROJECT SUMMARY/ABSTRACT Triple-negative breast cancer (TNBC) is challenging to treat clinically as it is highly invasive, has a high risk of relapse, metastasizes, and has a very poor prognosis. Patients experience disease progression even with improved chemotherapy, immunotherapy, and surgery. About 40% of stage…